The biopharmaceutical company took the opportunity this week to outline its milestones for 2016. Prometic’s shares have not escaped the turmoil that has engulfed global markets of late with the shares down some 32% over the last month. We believe the fundamentals for the business remain compelling and that this may be an opportunistic entry point. The milestones discussed focused on three core programmes.
12 Feb 2016
2016 milestones point to pivotal year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2016 milestones point to pivotal year
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
12 Feb 2016 -
Author:
Derren Nathan -
Pages:
6
The biopharmaceutical company took the opportunity this week to outline its milestones for 2016. Prometic’s shares have not escaped the turmoil that has engulfed global markets of late with the shares down some 32% over the last month. We believe the fundamentals for the business remain compelling and that this may be an opportunistic entry point. The milestones discussed focused on three core programmes.